Study of Participants With Crohn's Disease and Ulcerative Colitis in Eastern Europe, Middle East, and North Africa (P08166)
Withdrawn
- Conditions
- Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative Colitis
- Registration Number
- NCT01293656
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This study is being done to assess the clinical course and treatment options for Crohn's Disease (CD) and ulcerative colitis (UC) in the populations of Eastern Europe, Middle East, and North Africa.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Confirmed diagnosis of Crohn's disease or ulcerative colitis.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The number of participants with different degrees of CD and UC severity. 1 Year Use rates of classes of drug therapy. 1 Year Number and types of surgical interventions. 1 Year The number of participants with Crohn's Disease (CD) or ulcerative colitis (UC) who visit the participating sites. 1 Year Outcomes of surgical intervention. 1 Year
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Crohn's disease and ulcerative colitis in Eastern European, Middle Eastern, and North African populations according to NCT01293656?
How do treatment patterns for inflammatory bowel disease in NCT01293656 compare with standard-of-care therapies in Western countries?
What biomarkers are associated with disease severity and treatment response in Crohn's disease and ulcerative colitis as identified in the NCT01293656 observational study?
What adverse events are commonly reported in Eastern European, Middle Eastern, and North African patients with inflammatory bowel disease based on NCT01293656 data?
How do the findings from NCT01293656 contribute to the understanding of therapeutic approaches for Crohn's disease and ulcerative colitis, particularly in relation to Merck Sharp & Dohme LLC's research portfolio?